Found 202 articles for: "chemotherapy"
Vismodegib: A Hedgehog Pathway Inhibitor for Locally Advanced and Metastatic Basal Cell Carcinomas
October 2013 | Volume 12 | Issue 10 | Supplement Individual Articles | 154 | Copyright © October 2013
Basal cell carcinomas (BCCs) are the most common cancer in the United States, and the overwhelming majority of BCCs are the result of hedgehog pathway activation. While locally advanced and metastatic...
Read MoreThe Impact of Inoperable Advanced Basal Cell Carcinoma: the Economic, Physical, and Psychological Burden of the Disease
October 2013 | Volume 12 | Issue 10 | Supplement Individual Articles | 151 | Copyright © October 2013
The development of vismodegib and its recent approval by the United States Food and Drug Administration for use in patients with locally advanced or metastatic basal cell carcinoma (BCC) carries with ...
Read MoreTreatment of Margin Positive Basal Cell Carcinoma With Vismodegib: Case Report and Consideration of Treatment Options and Their Implications
October 2013 | Volume 12 | Issue 10 | Supplement Individual Articles | 147 | Copyright © October 2013
Historically, basal cell carcinomas (BCCs) that are neither surgically resectable nor candidates for radiation therapy have had few treatment options. The hedgehog pathway inhibitor, vismodegib, repre...
Read MoreClinical Trial Review
October 2013 | Volume 12 | Issue 10 | Features | 1191 | Copyright © October 2013
Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select...
Read MoreNews, Views and Reviews
October 2013 | Volume 12 | Issue 10 | Features | 1185 | Copyright © October 2013
Clinical Trial Review
September 2013 | Volume 12 | Issue 9 | Features | 1068 | Copyright © September 2013
Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select...
Read MoreCutaneous Lupus Erythematosus in a Patient Undergoing Intravitreal Bevacizumab Injections: Case Report and Review of the Literature
September 2013 | Volume 12 | Issue 9 | Case Reports | 1052 | Copyright © September 2013
INTRODUCTION: Bevacizumab is a recombinant humanized antibody against vascular endothelial growth factor (VEGF). It is approved by the Food and Drug Administration (FDA) for metastatic colorectal canc...
Read MoreNatural Ingredients in Atopic Dermatitis and Other Inflammatory Skin Disease
September 2013 | Volume 12 | Issue 9 | Supplement Individual Articles | 128 | Copyright © September 2013
Active naturals in dermatology have been experiencing a renaissance. Many of the naturals that have been known for centuries to be effective for various skin conditions have now been scientifically va...
Read MoreClinical Trial Review
August 2013 | Volume 12 | Issue 8 | Features | 959 | Copyright © August 2013
Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select...
Read MorePipeline Previews
August 2013 | Volume 12 | Issue 8 | Features | 955 | Copyright © August 2013
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from th...
Read MoreEfficacy, Tolerability, and Pharmacodynamics of Apremilast in Recalcitrant Plaque Psoriasis: A Phase II Open-Label Study
August 2013 | Volume 12 | Issue 8 | Original Article | 888 | Copyright © August 2013
BACKGROUND: Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II, multicenter, open...
Read MoreNews, Views, and Reviews. Myocosis Fungoides-An Update on a Non-Mycotic Disease
July 2013 | Volume 12 | Issue 7 | Features | 825 | Copyright © July 2013
Mycosis fungoides was first described in 1806 by the French physician Jean Louis Alibert in a patient whose skin lesions developed into mushroom-like tumors. Though it is not an infectious disease,...
Read MoreAcitretin Prescribing Patterns in Women of Childbearing Potential
July 2013 | Volume 12 | Issue 7 | Original Article | 799 | Copyright © July 2013
BACKGROUND: Acitretin is indicated for severe psoriasis, but it is also a potent teratogen whose use should be avoided in women of childbearing potential. Topical medications, phototherapy, cyclospori...
Read More40 Years of Topical Tretinoin Use in Review
June 2013 | Volume 12 | Issue 6 | Original Article | 638 | Copyright © June 2013
Topical tretinoin has been approved for use in dermatology for 40 years and is currently approved for the treatm...
Read MoreSign and Pseudo-Sign of Leser-Trélat: Case Reports and a Review of the Literature
May 2013 | Volume 12 | Issue 5 | Original Article | 79 | Copyright © May 2013
BACKGROUND: Leser-Trélat is distinguished by a rare paraneoplastic sign that is characterized by the sudden eruption of multiple seborrheic keratoses (SKs), associated with underlying internal ma...
Read MoreClinical Trial Review
May 2013 | Volume 12 | Issue 5 | Features | 596 | Copyright © May 2013
Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select...
Read MoreNontraditional Management of Basal Cell Carcinoma
May 2013 | Volume 12 | Issue 5 | Original Article | 525 | Copyright © May 2013
This review discusses nontraditional modalities available for the treatment of basal cell carcinoma along with the existing evidence to support their respective uses in varying clinical situations. By...
Read MoreClinical Trial Review
April 2013 | Volume 12 | Issue 4 | Features | 496 | Copyright © April 2013
Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select ...
Read MoreCase Experience of 308-nm Excimer Laser Therapy Compatibility With PUVA and Oral Bexarotene for the Treatment of Cutaneous Lesions in Mycosis Fungoides
April 2013 | Volume 12 | Issue 4 | Case Reports | 487 | Copyright © April 2013
Little is known about the safety and effectiveness of excimer laser therapy when used in conjunction with other therapies in the treatment of mycosis fungoides (MF) lesions. We describe the use of adj...
Read MoreKeloids: An Update on Medical and Surgical Treatments
April 2013 | Volume 12 | Issue 4 | Original Article | 403 | Copyright © April 2013
Keloids are the result of an overgrowth of dense fibrous tissue that usually develops after healing of a skin injury. Despite their common occurrence, keloids remain one of the most challenging dermat...
Read More